A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense ...

Researchers from University of Kentucky report that antisense inhibition of CD47 improved glucose homeostasis, insulin ...

Researchers from the USC Norris Comprehensive Cancer Center and collaborators report that they have found evidence that targeting CD47, a protein that is part of the innate immune system, could be a ...

ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted ...

A characteristic of tumors includes the ability to avoid the immune system. In many cases tumors can progress without detection of immune cells. In the literature many scientists refer to undetectable ...

First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...

Researchers at Kobe University discovered an entirely new and unexpected mechanism by which the immune system can get rid of cells lacking molecules that identify them as part of the self in mice. The ...

Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.

NSCLC is the leading cause of cancer deaths globally, with EGFR mutations being a common feature in these cancers. Osimertinib has shown significant improvements in progression-free survival for ...

Gilead Sciences' CD47 cancer program is back on track—for the most part—after the FDA lifted clinical holds placed in January on five trials. But the agency is keeping two additional trials on ice, ...

CD47-null femoral fractures show reduced bone formation, but increased tissue mineral density. µCT analysis of transverse femoral fracture in WT (n = 9) and CD47-null (n = 11-14) mice at 10- and ...